The immune regulation and therapeutic potential of the SMAD gene family in breast cancer

• Published in: Scientific reports Vol. 14; no. 1; p. 6769
• Main Authors: Chen, Zhuo, Wang, Yu, Lu, Xiaodi, Chen, Hong, Kong, Yiran, Rong, Liwei, Wang, Guonian
• Format: Journal Article
• Language: English
• Published: London Nature Publishing Group UK 21.03.2024; Nature Publishing Group; Nature Portfolio
• Subjects: 631/114; 631/67; 692/699; Apoptosis; Breast cancer; Cell cycle; Drug; Gene expression; Genes; Humanities and Social Sciences; Immune; Immunoregulation; Immunosuppressive agents; Infiltration; Metastases; multidisciplinary; Pathways; Point mutation; Science; Science (multidisciplinary); Signal transduction; SMAD family genes; Smad protein; Smad2 protein; Smad3 protein; Smad4 protein; Smad7 protein; Staurosporine; Transforming growth factor-b; Tumorigenesis; Drug; Breast cancer; Pathways; SMAD family genes; Immune
• DOI: 10.1038/s41598-024-57189-6
• ISSN: 2045-2322

Breast cancer is a serious threat to human health. The transforming growth factor-β signaling pathway is an important pathway involved in the occurrence and development of cancer. The SMAD family genes are responsible for the TGF-β signaling pathway. However, the mechanism by which genes of the SMAD family are involved in breast cancer is still unclear. Therefore, it is necessary to investigate the biological roles of the SMAD family genes in breast cancer. We downloaded the gene expression data, gene mutation data, and clinical pathological data of breast cancer patients from the UCSC Xena database. We used the Wilcox test to estimate the expression of genes of the SMAD family in cancers. And the biological functions of SMAD family genes using the DAVID website. The Pearson correlation method was used to explore the immune cell infiltration and drug response of SMAD family genes. We conducted in biological experiments vitro and vivo. In this study, we integrated the multi-omics data from TCGA breast cancer patients for analysis. The expression of genes of SMAD family was significantly dysregulated in patients with breast cancer. Except for SMAD6, the expression of other SMAD family genes was positively correlated. We also found that genes of the SMAD family were significantly enriched in the TGF-β signaling pathway, Hippo signaling pathway, cell cycle, and cancer-related pathways. In addition, SMAD3, SMAD6, and SMAD7 were lowly expressed in stage II breast cancer, while SMAD4 and SMAD2 were lowly expressed in stage III cancer. Furthermore, the expression of genes of the SMAD family was significantly correlated with immune cell infiltration scores. Constructing a xenograft tumor mouse model, we found that SMAD3 knockdown significantly inhibited tumorigenesis. Finally, we analyzed the association between these genes and the IC50 value of drugs. Interestingly, patients with high expression of SMAD3 exhibited significant resistance to dasatinib and staurosporine, while high sensitivity to tamoxifen and auranofin. In addition, SMAD3 knockdown promoted the apoptosis of BT-549 cells and decreased cell activity, and BAY-1161909 and XK-469 increased drug efficacy. In conclusion, genes of the SMAD family play a crucial role in the development of breast cancer.